Journals / Türk Fertilite Dergisi / 2005 / Cilt: 13 - Sayı: 3

The etiopathogenetic factors which figure in the development of polycystic ovary syndrome

Polikistik over sendromu gelişiminde rolü olan etyopatogenetik faktörler

Pages
229–237
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Assuming the etiopatho genetic factors entirely become very important for the diagnosis, trial, treatment of the disease and also for the prevention of complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To define the polycystic ovary syndrome according to different criteria and to investigate the diversity of the etiopathogenetic factors which figure in the development of polycystic ovary syndrome.
📊
Key Findings & Data:Method: Polycystic ovary syndrome was first described by Stein and Leventhal in 1935.
💡
Conclusion & Impact:Conclusion: Assuming the etiopatho genetic factors entirely become very important for the diagnosis, trial, treatment of the disease and also for the prevention of complications.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To define the polycystic ovary syndrome according to different criteria and to investigate the diversity of the etiopathogenetic factors which figure in the development of polycystic ovary syndrome. Method: Polycystic ovary syndrome was first described by Stein and Leventhal in 1935. The clinical diagnosis was based on the triad of amenorrhea, hirsutism and obesity in past years. On the other hand recent studies have shown that PCOS has an extensive, heterogen clinical view and multifactorial etiology. Hyperandrogenism and anovulation seen in PCOS are arised endocrinogically as a consequence of the anomalies of 4 compartments: over, adrenal gland, skin and fat tissue, hypothalamic-pituitary axis. However the alterations of hypothalamic-pituitary-ovarian axis, intrinsic ovary pathology, synergy of peripubertal exagere ad-renarge and physiological insulin resistance, obesity, pathologic insulin resistance and beta cell disfunction of pancreas and the role of familial aggregation indicating the genetic etiology have been definitely revealed in the etiopatho genesis of PCOS, studies are currently carried on this subject. In this review the definition of PCOS according to different criteria and the variable etiopatho genetic factors that figure in the development of this syndrome are explained. Conclusion: Assuming the etiopatho genetic factors entirely become very important for the diagnosis, trial, treatment of the disease and also for the prevention of complications.

Özet

Amaç: Polikistik Over Sendromunun farklı kriterlere göre tanımlanması ve bu sendromun gelişiminde rol alan etyopatogenetik faktörlerdeki çeşitliliğin araştırılmasıdır. Method: Polikistik Over Sendromu ilk olarak 1935'de Stein ve Leventhal tarafından tanımlanmıştır. Geçmiş yıllarda klinik tanı amenore, hirsutizm, obesite triadından oluşmaktaydı. Ancak son zamanlarda yapılan çalışmalar ise PKOS'nun geniş, heterojen bir klinik tabloya ve multifaktöriyel bir etyolojiye sahip olduğunu göstermiştir. PKOS'da görülen hiperandrojenizm ve anovulasyon endokrinolojik olarak 4 kompartmanda görülen anormallikler sonucu ortaya çıkar; over, adrenal bez, cilt ve yağ dokusu, hipotalamo-hipofizer aks. PKOS'nda etyopatogenez.de hipotalamo-ptuiter-overyen akstaki değişiklikler, intrinsik over patolojisi, peripubertal ekzajere adrenarş ve fizyolojik insülin rezistansının birlikteliği, obezite, patolojik insülin rezistansı ve pankreasla beta hücre disfonksiyonu ve genetik etyolojiye işaret eden ailesel birikimin rolü kesin olarak gösterilmekle beraber bu konuda halen çalışmalar devam etmektedir. Bu derlemede 'PKOS'nun farklı kriterlere göre tanımlanması ve sendromun gelişiminde rol alan çeşitli etyopatogenetik faktörler anlatılmaktadır. Sonuç: PKOS'da etyopatogenetik faktörlerin tam olarak bilinmesi; hastalığın tanısı, izlemi, tedavisi ve uzun dönem komplikasyonların gelişiminin engellenmesi açısından çok büyük bir önem kazanmaktadır.

🔖

Cite This Article

BAYRAM, M., SEVİNÇ, F. C., SOYER, C. (2022). The etiopathogenetic factors which figure in the development of polycystic ovary syndrome. Türk Fertilite Dergisi, Cilt: 13 - Sayı: 3, 229–237. https://ajindex.com/articles/623335

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Stein IF, Leventhal MI; Amenorrhea associated with bilateral polycystic ovaries, Am J Obstet Gynecol 29. 181, 1935 2. Berek Jonathan S., Hershlag A., Peterson CM., Endocrine Disorders Novak Gynecology 13th Edition.
  2. USA, Lippincott Williams And Wilkins 2002: 871-930. 3. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome towards a rational approach. In: Dunaif A, Givens JR, Hasekine FP, et al, eds. Polycystic Ovary Syndrome. Blacwell Scientific, 1992: 377-384 4. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004 19 (1): 41-47. 5. Franks S.; Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf). 1989 Jul;31(1 ):87-120 6. GoldzieherJW.; Polycystic ovarian disease. Fertil Steril. 1981 Apr;35(4):371-94. Review 7. Dahlgren E.; Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992 Dec;71(8):599-604 8. Balen AH; Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995 Aug;10(8):2107-11 9. Conway G.S.; Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol {Oxf). 1989 Apr; 30(4):459-70 10. Dunaif A.; Evidence for distinctive and intrinsic defects in insulin ^action in polycystic ovary syndrome. Diabetes. 1992 Oct;41(10):1257-66. 11. Goudas VT.; Polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1997 Dec;26(4):893-912. Review ■12. Goldzieher JW.; Clinical and biochemical features of polycystıc ovarian disease. Fenil Steril. 1963 Nov-Dec; 14:631-53. 13. Aono T; Responses of serum gonadotrophins to LH-releasing hormone and oestrogens in Japanese women with polycystic ovaries. Açta Endocrinol (Copenh). 1977 Aug;85(4):840-9. 14. Serafini P.; 5 alpha-Reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab. 1985 Feb;60(2):349-55. 15. Knochenhauer E.; Ovarian hormones and adrenal androgens during a woman's life span. J Am Acad Dermatol. 2001 Sep;45(3 Suppl):SJ05-15. Review 16. Carmina E, hobo RA. Do hyperandrogenie women with normal menses have polycystic ovary syndrome? Fertil Steril. 1999 Feb;7J(2):319-22. 17. Creswell JL; Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet. 1997 Oct 18;350(9085):